Evotec has deepened its relationship with artificial intelligence company Exscientia by investing €15m in the UK-based company; the CRO wants to build on the pair's existing collaboration in immuno-oncology and use its stake to diversify the AI firm's portfolio.
Evotec AG has made a €15m investment in artificial intelligence-driven drug discovery company, Exscientia Ltd. – becoming its first strategic shareholder.
The two companies are not strangers and this buy in builds upon their existing drug discovery partnership in immuno-oncology.
Create an account to read this article
Already a subscriber?
Experts from UCB, Alnylam, Lantheus and Medtronic deliberated at a recent summit best uses of agentic AI in the MLR review process, its human replaceability quotient and ways to balance creativity with compliance, a significant discussion amid DTC advertising and US FDA scrutiny.
At the annual biopharma confab, biopharma execs shared their thoughts about where artificial intelligence is heading and pharma avoiding following the leader in hot areas.
The drugmaker announced it would work with the tech giant to deploy a supercomputer that it will use to train AI models and enhance drug discovery, development and manufacturing.
One panelist at the BioFuture conference said AI is a bubble, but that when the bubble bursts it will leave a lot of innovation in its wake.
Speakers at the BioFuture conference discussed how confusing the policy environment has become, skepticism about AI/ML in drug development, the future of cancer immunotherapy, ideas for accelerating rare disease therapies and where the biopharma financing market is going.
Takeda's APAC chief talks about driving affordability and access for products like Adcetris and Qdenga, focusing on the region's diverse needs. “Watch this space” he said on the Japanese group’s Innovation Capability Centers, as they shape digital solutions to transform operations.
The drugmaker launched TuneLab, part of Catalyze360, which gives partners access to its artificial intelligence/machine learning drug discovery model trained on its research data.
